`___________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________
`
`AFFORDABLE DRUGS V LLC,
`Petitioner,
`
`v.
`
`BIOGEN MA INC.,
`Patent Owner.
`
`____________________________________________
`
`Case: IPR2015-01993
`U.S. Patent No. 8,399,514
`____________________________________________
`
`PATENT OWNER’S EXHIBIT LIST
`(as of January 6, 2016)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibits
`Description
`Exhibit 2001 Hayman Capital Management, L.P. Form ADV Part 2A
`Brochure, June 1, 2015
`
`Exhibit 2002 First Amended Petition in IPR2015-01136 (Paper No. 9)
`Exhibit 2003 Biogen’s Preliminary Response in IPR2015-01136 (Paper No.
`21)
`
`Exhibit 2004 Declaration of Dr Linberg in IPR2015-01136 (Exhibit 1005A)
`
`Exhibit 2005
`
`Ludwig Kappos et al.,“A Randomized, Placebo-Controlled
`Phase 2 Trial of a Novel Oral Fumarate, BG00012, in Patients
`With Relapsing-Remitting Multiple Sclerosis,” from the 15th
`meeting of the European Neurological Society, Vienna Austria
`(June 18-22, 2005) (presented on June 20, 2005)
`
`Exhibit 2006
`
`Final Program for Fifteenth Meeting of the European
`Neurological Society, June 18-22, 2005, Vienna Austria
`(http://www.congrex.ch/2005/ens2005/)
`
`Exhibit 2007
`
`Scientific Program from Fifteenth Meeting of the European
`Neurological Society, June 18-22, 2005
`(http://registration.akm.ch/einsicht.php?XNKONGRESS_ID=1
`8&XNSPRACHE_ID=2)
`
`Exhibit 2008
`
`Program from Wednesday, June 22, 2005 from Fifteenth
`Meeting of the European Neurological Society
`(http://registration.akm.ch/einsicht.php?XNKONGRESS_ID=1
`8&XNSPRACHE_ID=2&XNMASKEN_ID=200&XSDATUM
`=2005-06-20)
`Exhibit 2009 Final Office Action dated October 12, 2012, in U.S. Patent
`Application No. 13/372,426
`Exhibit 2010 Reply to Final Office Action filed December 12, 2012, in U.S.
`Patent Application No. 13/372,426
`Exhibit 2011 Declaration of Richard A. Rudick, M.D. Under 37 C.F.R.
`§1.132 filed on August 3, 2012 in U.S. Patent Application No.
`1
`
`
`
`
`
`
`
`Exhibits
`
`Description
`13/372,426
`Exhibit 2012 Notice of Allowance and Fees Due dated December 26, 2012 in
`U.S. Patent Application No. 13/372,426
`Poster Session 5, Multiple Sclerosis, Wednesday, June 22, 2005
`from Fifteenth Meeting of the European Neurological Society
`(http://registration.akm.ch/einsicht.php?XNMASKEN_ID=300
`&XNKONGRESS_ID=18&XNSPRACHE_ID=2&XNSESSIO
`N_ID=748)
`
`Exhibit 2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`Dated: January 6, 2016
`
`
`
`
`Respectfully submitted,
`
`By: / Maureen D. Queler /
`Michael J. Flibbert, Reg. No. 33,234
`Maureen D. Queler, Reg. No. 61,879
`Finnegan, Henderson, Farabow, Garrett
`& Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`(202) 408-4000
`
`Counsel for Patent Owner
`
`
`
`2
`
`
`
`
`
`
`
`CERTIFICATE OF SERVICE
`
`The undersigned hereby certifies that copies of the foregoing PATENT
`
`OWNER’S EXHIBIT LIST and Exhibits 2001-2013 were served on January 6,
`
`2016, via electronic mail directed to counsel of record for the Petitioner at the
`
`following:
`
`Robert W. Hahl
`Neifeld IP Law, PC, 4813-B Eisenhower Avenue,
`Alexandria, VA 22304
`rhahl@neifeld.com
`
`Robert Mihail
`Neifeld IP Law, PC, 4813-B Eisenhower Avenue,
`Alexandria, VA 22304
`rmihail@neifeld.com
`
`John K. Pike
`Neifeld IP Law, PC, 4813-B Eisenhower Avenue,
`Alexandria, VA 22304
`Email: jkpike@neifeld.com
`
`general@neifeld.com
`
`Petitioner has agreed to electronic service.
`
`Dated: January 6, 2016
`
`
`By: / Maureen D. Queler /
` Maureen D. Queler
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`FINNEGAN, HENDERSON, FARABOW,
`GARRETT & DUNNER, LLP